MCL-1 is a clinically targetable vulnerability in breast cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018;8(5):180002.
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Leung HY. Evasion of cell death: a contributory factor in prostate cancer development and treatment resistance. Cancer Letters. 2021;520:213–221.
   PubMed Web of Science ®Google Scholar
• Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101–1104.
   PubMed Web of Science ®Google Scholar
• Wang X,Bathina M, Lynch J, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27(12):1351–1364.
   PubMed Web of Science ®Google Scholar
• Thomas RL,Roberts DJ,Kubil DA, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27(12):1365–1377.
   PubMed Web of Science ®Google Scholar
• Beroukhim R,Porter D,Wei G, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226(4678):1097–1099.
   PubMed Web of Science ®Google Scholar
• Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41(3):899–906.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A. 1985;82(21):7439–7443.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440–442.
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nuñez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334–336.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25(1):27–36.
   PubMed Web of Science ®Google Scholar
• Certo M, Moore VDG, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–365.
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393–403.
   PubMed Web of Science ®Google Scholar
• Kuwana T,Bouchier-Hayes L,Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17(4):525–535.
   PubMed Web of Science ®Google Scholar
• Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-x L-bak peptide complex: recognition between regulators of apoptosis. Science. 1997;275(5302):983–986.
   PubMed Web of Science ®Google Scholar
• Liu XQ, Dai S, Zhu Y, et al. The structure of a Bcl-x(L)/Bim fragment complex: implications for bim function. Immunity. 2003;19(3):341–352.
   PubMedGoogle Scholar
• Zou H, Henzel WJ, Liu X, et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90(3):405–413.
   PubMed Web of Science ®Google Scholar
• Kluck RM, Bossy-Wetzel E, Green DR, et al. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132–1136.
   PubMed Web of Science ®Google Scholar
• Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates Bid, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7(12):1166–1173.
   PubMed Web of Science ®Google Scholar
• Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2(3):183–192.
   PubMed Web of Science ®Google Scholar
• Goldstein JC,Waterhouse NJ,Juin P, et al. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000;2(3):156–162.
   PubMed Web of Science ®Google Scholar
• Kozopas KM,Yang T, Buchan HL, et al. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993;90(8):3516–3520.
   PubMed Web of Science ®Google Scholar
• Zhou P, Qian L, Kozopas KM, et al. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89(2):630–643.
   PubMed Web of Science ®Google Scholar
• Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-x L -Bak Peptide Complex: recognition Between Regulators of Apoptosis. Science. 1997;275(5302):983–986.
   PubMed Web of Science ®Google Scholar
• Liu X, Dai S, Zhu Y, et al. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity. 2003;19(3):341–352.
   PubMedGoogle Scholar
• Czabotar PE,Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A. 2007;104(15):6217–6222.
   PubMed Web of Science ®Google Scholar
• Day CL,Chen L,Richardson SJ, et al. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem. 2005;280(6):4738–4744.
   PubMed Web of Science ®Google Scholar
• Mei Y,Du W, Yang Y, et al. Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1. Oncogene. 2005;24(48):7224–7237.
   PubMedGoogle Scholar
• Lee EF,Czabotar PE,Van Delf MF, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol. 2008;180(2):341–355.
   PubMed Web of Science ®Google Scholar
• van Delft MF,Wei AH,Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–399.
   PubMed Web of Science ®Google Scholar
• Karbon G,Haschka MD,Hackl H, et al. The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents. Cell Death Dis. 2021;12(12):1151.
   PubMedGoogle Scholar
• Floros KV,Lochmann TL,Hu B, et al. Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A. 2018;115(11):E2594–e2603.
   PubMedGoogle Scholar
• Sørlie T,Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874.
   PubMed Web of Science ®Google Scholar
• Prat A,Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.
   PubMed Web of Science ®Google Scholar
• Cerami E,Allen GI,Liu Z, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Gao J,Aksoy BA,Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):1.
   Web of Science ®Google Scholar
• Pereira B,Chinn SF,Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.
   PubMed Web of Science ®Google Scholar
• Lefebvre C, et al. Mutational Profile of Metastatic Breast Cancers: a Retrospective Analysis. PLoS Med. 2016;13(12):e1002201.
   PubMed Web of Science ®Google Scholar
• Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
   PubMed Web of Science ®Google Scholar
• Xu Y, et al. ERα is an RNA-binding protein sustaining tumor cell survival and drug resistance. Cell; 2021.
   Google Scholar
• Campbell KJ, et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 2018;9(2):19.
   PubMedGoogle Scholar
• Jeselsohn R, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20(7):1757–1767.
   PubMed Web of Science ®Google Scholar
• Gasca J, et al. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. Oncotarget; 2016.
   Google Scholar
• Balko JM, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–245.
   PubMed Web of Science ®Google Scholar
• Lee KM, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26(4):633–647.e7.
   PubMed Web of Science ®Google Scholar
• Booy EP, Henson ES, Gibson SB. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene. 2011;30(20):2367–2378.
   PubMedGoogle Scholar
• Townsend KJ, et al. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem. 1999;274(3):1801–1813.
   PubMedGoogle Scholar
• Senichkin VV, et al. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27(2):405–419.
   PubMedGoogle Scholar
• Cavarretta IT, et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol. 2008;617:547–555.
   PubMed Web of Science ®Google Scholar
• Berishaj M, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9(3):R32.
   PubMed Web of Science ®Google Scholar
• Siersbæk R, et al. IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis. Cancer Cell. 2020;38(3):412–423.e9.
   PubMedGoogle Scholar
• Jourdan M, et al. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ. 2000;7(12):1244–1252.
   PubMedGoogle Scholar
• Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570–2578.
   PubMed Web of Science ®Google Scholar
• Salgado R, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103(5):642–646.
   PubMed Web of Science ®Google Scholar
• Gregory GP, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia. 2015;29(6):1437–1441.
   PubMed Web of Science ®Google Scholar
• Floros KV, et al. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell Death Dis. 2021;12(2):179.
   PubMedGoogle Scholar
• Cidado J, et al. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clin Cancer Res. 2020;26(4):922–934.
   PubMed Web of Science ®Google Scholar
• Dey J, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017;7(1):18007.
   PubMedGoogle Scholar
• Phillips DC, et al. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020;34(6):1646–1657.
   PubMedGoogle Scholar
• Liu H, et al. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol. 2005;25(8):3117–3126.
   PubMedGoogle Scholar
• Mills JR, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A. 2008;105(31):10853–10858.
   PubMedGoogle Scholar
• Tailler M, et al. By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737. Cell Death Differ. 2019;26(9):1766–1781.
   PubMedGoogle Scholar
• Vega F, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66(13):6589–6597.
   PubMedGoogle Scholar
• Wei G, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10(4):331–342.
   PubMed Web of Science ®Google Scholar
• Wendel HG, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232–3237.
   PubMed Web of Science ®Google Scholar
• Fu NY, et al. EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nat Cell Biol. 2015;17(4):365–375.
   PubMed Web of Science ®Google Scholar
• Anderson GR, et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci Transl Med. 2016;8(369):369ra175.
   PubMedGoogle Scholar
• Germain M, Duronio V. The N terminus of the anti-apoptotic BCL-2 homologue MCL-1 regulates its localization and function. J Biol Chem. 2007;282(44):32233–32242.
   PubMed Web of Science ®Google Scholar
• Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986;234(4774):364–368.
   PubMed Web of Science ®Google Scholar
• Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol. 1995;128(6):1173–1184.
   PubMedGoogle Scholar
• Ding Q, et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007;27(11):4006–4017.
   PubMedGoogle Scholar
• Ding Q, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008;68(15):6109–6117.
   PubMed Web of Science ®Google Scholar
• Domina AM, et al. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23(31):5301–5315.
   PubMed Web of Science ®Google Scholar
• Harley ME, et al. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. Embo J. 2010;29(14):2407–2420.
   PubMed Web of Science ®Google Scholar
• Ding Q, et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007;67(10):4564–4571.
   PubMedGoogle Scholar
• Zhong Q, et al. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005;121(7):1085–1095.
   PubMed Web of Science ®Google Scholar
• Warr MR, et al. BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett. 2005;579(25):5603–5608.
   PubMedGoogle Scholar
• Balko JM, et al. molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–245.
   PubMed Web of Science ®Google Scholar
• Akhoondi S, et al. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 2010;12(6):R105.
   PubMedGoogle Scholar
• Schwickart M, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463(7277):103–U114.
   PubMed Web of Science ®Google Scholar
• Wu X, et al. JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. Cell Death Differ. 2020;27(1):55–70.
   PubMedGoogle Scholar
• Wu X, et al. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. Proc Natl Acad Sci U S A. 2019;116(8):2961–2966.
   PubMedGoogle Scholar
• Kabir S, et al. The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells. Elife. 2019;8.
   PubMed Web of Science ®Google Scholar
• Wang B, et al. Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell Death Differ. 2014;21(7):1160–1169.
   PubMed Web of Science ®Google Scholar
• Zhang S, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9(1):215.
   PubMedGoogle Scholar
• Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020;11(7):556.
   PubMed Web of Science ®Google Scholar
• Wang Z, et al. Proteolysis targeting chimeras for the selective degradation of mcl-1/bcl-2 derived from nonselective target binding ligands. J Med Chem. 2019;62(17):8152–8163.
   PubMed Web of Science ®Google Scholar
• Papatzimas JW, et al. From Inhibition to Degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1). J Med Chem. 2019;62(11):5522–5540.
   PubMed Web of Science ®Google Scholar
• Oda E, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053–1058.
   PubMed Web of Science ®Google Scholar
• Shibue T, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003;17(18):2233–2238.
   PubMed Web of Science ®Google Scholar
• Villunger A, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036–1038.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681.
   PubMed Web of Science ®Google Scholar
• Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.
   PubMed Web of Science ®Google Scholar
• Mason KD, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173–1186.
   PubMed Web of Science ®Google Scholar
• Wilson WH, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149–1159.
   PubMed Web of Science ®Google Scholar
• Oakes SR, Vaillant F, Lim E, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci U S A. 2012;109(8):2766–2771.
   PubMed Web of Science ®Google Scholar
• Balachander SB, et al. Abstract 56: AZD0466, a nanomedicine of a potent dual Bcl2/Bcl-xl inhibitor, exhibits anti–tumor activity in a range of henatological and solid tumor models. Cancer Research. 2020;80(16_Supplement):56.
   Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–240.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Perillo B, Sasso A, Abbondanza C, et al. 17beta-estradiol inhibits apoptosis in mcf-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol. 2000;20(8):2890–2901.
   PubMed Web of Science ®Google Scholar
• Vaillant F, Merino D, Lee L, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24(1):120–129.
   PubMed Web of Science ®Google Scholar
• Lok SW, Whittle JR, Vaillant F, et al. A phase ib dose-escalation and expansion study of the bcl2 inhibitor venetoclax combined with tamoxifen in er and bcl2-positive metastatic breast Cancer. Cancer Discov. 2019;9(3):354–369.
   PubMed Web of Science ®Google Scholar
• Whittle JR, Vaillant F, Surgenor E, et al. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2020;26(15):4120–4134.
   PubMed Web of Science ®Google Scholar
• Lindeman GJ, Bowen R, Jerzak KJ, et al. Results from VERONICA: a randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). J clin oncol. 2021;39(15_suppl):1.
   PubMedGoogle Scholar
• Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–482.
   PubMed Web of Science ®Google Scholar
• Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341.
   PubMed Web of Science ®Google Scholar
• Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective mcl1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8(12):1582–1597.
   PubMed Web of Science ®Google Scholar
• Ramsey HE, Fischer MA, Lee T, et al. A novel mcl1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566–1581.
   PubMed Web of Science ®Google Scholar
• Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33(4):905–917.
   PubMed Web of Science ®Google Scholar
• Lee T, et al. Discovery of potent myeloid cell leukemia-1 (mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer. J Med Chem. 2019;62(8):3971–3988.
   PubMedGoogle Scholar
• Xiao Y, Nimmer P, Sheppard GS, et al. MCL-1 is a key determinant of breast cancer cell survival: validation of mcl-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 2015;14(8):1837–1847.
   PubMed Web of Science ®Google Scholar
• Merino D, Whittle JR, Vaillant F, et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med. 2017;9(401).
   PubMed Web of Science ®Google Scholar
• Campbell KJ et al Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function, et al. Cell Death Differ. 2021;28(9): 2589–2600.
   PubMed Web of Science ®Google Scholar
• Goodwin CM, Rossanese OW, Olejniczak ET, et al. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015;22(12):2098–2106.
   PubMedGoogle Scholar
• Young AI, Law AMK, Castillo L, et al. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 2016;18(1):125.
   PubMedGoogle Scholar
• Petrocca F, Altschuler G, Tan S, et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013;24(2):182–196.
   PubMed Web of Science ®Google Scholar
• Williams MM,Lee, L, Hicks, D. J, et al. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Mol Cancer Res. 2017;15(3):259–268.
   PubMedGoogle Scholar
• Tsherniak A. Defining a cancer dependency map. Cell. 2017;170:564–576 e16.
   PubMed Web of Science ®Google Scholar
• Annunziato S,Henneman, L, Brambillasca, C. S, et al. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nat Commun. 2019;10(1):397.
   PubMedGoogle Scholar
• Meyers RM, Bryan JG, McFarland JM, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779–1784.
   PubMed Web of Science ®Google Scholar
• Dempster JM,Rossen, J., Kazachkova, M, et al. Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines. BioRxiv. 2019;720243.
   Google Scholar
• Williams MM, Elion DL, Rahman B, et al. Therapeutic inhibition of mcl-1 blocks cell survival in estrogen receptor-positive breast cancers. Oncotarget. 2019;10(52):5389–5402.
   PubMedGoogle Scholar
• Thrane S, Pedersen AM, Thomsen MBH, et al. A kinase inhibitor screen identifies mcl-1 and aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. 2015;34(32):4199–4210.
   PubMedGoogle Scholar
• Alcon C, Gómez Tejeda Zañudo JGT, Albert R, et al. ER+ breast cancer strongly depends on mcl-1 and bcl-xl anti-apoptotic proteins. Cells. 2021;10(7):1659.
   PubMedGoogle Scholar
• Rasmussen ML,Taneja, N., Neininger, A. C, et al. MCL-1 inhibition by selective bh3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. Science. 2020;23(4):101015.
   Google Scholar
• Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671–676.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, et al.
   Google Scholar
• Louault K, Bonneaud TL, Séveno C, et al. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene. 2019;38(17):3261–3273.
   PubMedGoogle Scholar
• Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163(5):2113–2126.
   PubMed Web of Science ®Google Scholar
• Lim E,Wu, D, Pal, B, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010;12(2):R21.
   PubMed Web of Science ®Google Scholar
• Creighton CJ,Li, X, Landis, M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106(33):13820–13825.
   PubMed Web of Science ®Google Scholar
• Echeverria GV,Ge, Z., Seth, S, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019;11(488).
   Google Scholar
• Montero J, Sarosiek K, DeAngelo J, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977–989.
   PubMed Web of Science ®Google Scholar
• Potter DS, Du R, Bhola P, et al. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. Cell Death Dis. 2021;12(8):741.
   PubMedGoogle Scholar